Home › Amarantus Receives Orphan Drug Designation For Eltoprazine
 

Keywords :   


Amarantus Receives Orphan Drug Designation For Eltoprazine

2016-02-11 06:24:55| drugdiscoveryonline News Articles

Amarantus BioScience Holdings, Inc.(OTCQB: AMBS),a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that it has received orphan drug designation from the US FDA for Eltoprazine in the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).

Tags: drug receives designation orphan

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
09.05Disney and Warner to bundle streaming services
09.05Whistleblower: Boeing supplier sent faulty parts
09.05Will AI dream up the hit TV shows of the future?
09.05Interest rates expected to stay at 16-year high
09.05Emma Roberts Is Kiko Milanos First Global Brand Ambassador
08.05New regulations and rules for public land management
08.05IBBA seeks Executive Vice President
08.05The 75th Brangus Celebration: Honoring heritage and innovation
More »